Ntlotlang Mokgautsi

Pharmacoinformatics and Preclinical Studies of NSC765690 and NSC765599, Potential STAT3/CDK2/4/6 Inhibitors with Antitumor Activities against NCI60 Human Tumor Cell Lines

Bashir Lawal, Yen‐Lin Liu, Ntlotlang Mokgautsi et al. · Biomedicines · 2021 · 52 citations · Full text

Molecular Docking, Chemoprevention Strategy, Antitumor Activities +15

mTOR/EGFR/iNOS/MAP2K1/FGFR/TGFB1 Are Druggable Candidates for N-(2,4-Difluorophenyl)-2′,4′-Difluoro-4-Hydroxybiphenyl-3-Carboxamide (NSC765598), With Consequent Anticancer Implications

Bashir Lawal, Ching‐Yu Lee, Ntlotlang Mokgautsi et al. · Frontiers in Oncology · 2021 · 51 citations · Full text

EGFR-upregulated LIFR promotes SUCLG2-dependent castration resistance and neuroendocrine differentiation of prostate cancer

Shian‐Ren Lin, Yu‐Ching Wen, Hsiu‐Lien Yeh et al. · Oncogene · 2020 · 38 citations

Urology, Suclg2-dependent Castration Resistance, Egfr-upregulated Lifr +5

HNC0014, a Multi-Targeted Small-Molecule, Inhibits Head and Neck Squamous Cell Carcinoma by Suppressing c-Met/STAT3/CD44/PD-L1 Oncoimmune Signature and Eliciting Antitumor Immune Responses

Jih-Chin Lee, Alexander T.H. Wu, Jia‐Hong Chen et al. · Cancers · 2020 · 34 citations · Full text

An Integrated Bioinformatics Study of a Novel Niclosamide Derivative, NSC765689, a Potential GSK3β/β-Catenin/STAT3/CD44 Suppressor with Anti-Glioblastoma Properties

Ntlotlang Mokgautsi, Ya-Ting Wen, Bashir Lawal et al. · International Journal of Molecular Sciences · 2021 · 28 citations · Full text